These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 21586342)

  • 1. Efficacy of Sevikar® compared to the combination of perindopril plus amlodipine on central arterial blood pressure in patients with moderate-to-severe hypertension: Rationale and design of the SEVITENSION study.
    Ruilope LM; Schaefer A
    Contemp Clin Trials; 2011 Sep; 32(5):710-6. PubMed ID: 21586342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
    Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of the efficacy of olmesartan/amlodipine vs. perindopril/amlodipine in peripheral blood pressure after missed dose in type 2 diabetes.
    Redon J; Pichler G;
    J Hypertens; 2016 Feb; 34(2):359-67. PubMed ID: 26867060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial effects of combination therapy with angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function.
    Morimoto S; Maki K; Aota Y; Sakuma T; Iwasaka T
    Hypertens Res; 2008 Aug; 31(8):1603-10. PubMed ID: 18971536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new dimension in hypertension management with the amlodipine/perindopril combination.
    Poulter NR
    J Hypertens; 2011 Dec; 29 Suppl 1():S15-21. PubMed ID: 22157563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
    Ogawa H; Kim-Mitsuyama S; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
    Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.
    Miranda RD; Mion D; Rocha JC; Kohlmann O; Gomes MA; Saraiva JF; Amodeo C; Filho BL
    Clin Ther; 2008 Sep; 30(9):1618-28. PubMed ID: 18840367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension.
    Jamerson KA; Nwose O; Jean-Louis L; Schofield L; Purkayastha D; Baron M
    Am J Hypertens; 2004 Jun; 17(6):495-501. PubMed ID: 15177521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
    Williams B; Lacy PS; Thom SM; Cruickshank K; Stanton A; Collier D; Hughes AD; Thurston H; O'Rourke M; ; ;
    Circulation; 2006 Mar; 113(9):1213-25. PubMed ID: 16476843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Optimization of BP Control and Arterial Elasticity With Fixed Combination Therapy Perindopril and Amlodipine In Patients With Arterial Hypertension and Increased Pulse Wave Velocity].
    Nedogoda SV; Konradi AO; Zvartau NE; Chumachek EV; Ledyaeva AA; Tsoma VV; Salasyuk AS; Judina JS; Smirnova VO; Khripaeva VJ; Palashkin RV
    Kardiologiia; 2017 Mar; 57(3):31-38. PubMed ID: 28762933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amlodipine besylate/olmesartan medoximil fixed combination for the treatment of hypertension.
    Chrysant SG
    Expert Rev Cardiovasc Ther; 2009 Aug; 7(8):887-95. PubMed ID: 19673666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension.
    Frampton JE; Scott LJ
    Am J Cardiovasc Drugs; 2009; 9(5):309-30. PubMed ID: 19791840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study.
    Punzi H; Neutel JM; Kereiakes DJ; Shojaee A; Waverczak WF; Dubiel R; Maa JF
    Ther Adv Cardiovasc Dis; 2010 Aug; 4(4):209-21. PubMed ID: 20519261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinations of inhibitors of the renin-angiotensin system with calcium channel blockers for the treatment of hypertension: focus on perindopril/amlodipine.
    Mourad JJ; Le Jeune S; Pirollo A; Mourad C; Gaudouen Y; Lopez-Sublet M
    Curr Med Res Opin; 2010 Sep; 26(9):2263-76. PubMed ID: 20690889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor.
    Hasler C; Nussberger J; Maillard M; Forclaz A; Brunner HR; Burnier M
    Clin Pharmacol Ther; 2005 Nov; 78(5):501-7. PubMed ID: 16321616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The fixed-dose combination of olmesartan/amlodipine was superior in central aortic blood pressure reduction compared with perindopril/amlodipine: a randomized, double-blind trial in patients with hypertension.
    Ruilope L; Schaefer A
    Adv Ther; 2013 Dec; 30(12):1086-99. PubMed ID: 24293132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients--an Anglo-Scandinavian cardiac outcomes trial substudy.
    Dolan E; Stanton AV; Thom S; Caulfield M; Atkins N; McInnes G; Collier D; Dicker P; O'Brien E;
    J Hypertens; 2009 Apr; 27(4):876-85. PubMed ID: 19516185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.